Iyo yechimurenga CAR T Cell Therapy iri kushandura mamiriro emabatiro atinoita cancer, kuita kuti ive yemunhu uye ine simba. Mushonga wazvino uno unoshandisa masero emuviri emurwere uye anoashandura kuti anange uye aparadze maseru egomarara zvine hungwaru hunoshamisa. Iri kutungamirira nzira kune mangwana akajeka, ane hutano!
Wakambofunga nezve kugona kunoshamisa kwemiviri yedu ine?
Kana zvisina kudaro, inguva yekuwana ruzivo pamusoro peiyi nyaya yakakosha.
Zvakanaka, ko kana ndikakuudza kuti masero ako chaiwo anogona kuita semagamba, kurwisa zvirwere zvinouraya segomarara nemazvo asingaenzaniswi?
Zvinganzwika sengano dzesainzi. Asi fungidzira chii? Iri simba rechimurenga riri kuita mafungu chinyararire, uye rinodanwa CAR T Cell Therapy!
Tinokukoka iwe kuti unzwisise zvakadzama zvakadzama zve CAR T Sero kuita nhanho nhanho, kusanganisira kuti masero aya anorimwa, anogadziridzwa, uye anodzoserwa mumuviri wako zvakare kuti arwise cancer.
Saka, kunyangwe iwe uchingoda kuziva nezve kurapwa uku kana munhu akabatwa negomarara rinouraya, ramba uchiverenga gwaro iri kuti unzwisise simba rekurapa uku kunovimbisa.
Kunzwisisa CAR T Cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy kufambira mberi kwakakosha mukurapa cancer kwavepo mumakore achangopfuura, kunounza tariro nyowani nemikana.
Kuti tinzwisise CAR T-cell therapy, ngatitarisei immune system yako semauto anoshanda anochengetedza muviri wako kune vanopinda, kusanganisira. kenza masero.
Vatambi vakakosha mune iyi nzira yekudzivirira ndeye T-masero-machena masero eropa akashongedzerwa nemareceptor anoita seayo immune system inoongorora. Aya mareceptor anoona kutyisidzira segomarara nekunanga mapuroteni anozivikanwa semaantigen ari pamusoro pemaseru anopinza.
Nekudaro, maseru egomarara akanaka pakuzvivanza kuti akwanise kuvanda kubva kumaT-seli ako. CAR T sero Therapy process inoedza kukunda dambudziko iri nekushandura T-cells kuita kenza-ekurwisa vamiririri.
Iyi nzira inosanganisira genetically modifying T-cells kuratidza Chimeric Antigen Receptors (CARs), iyo inoshanda sezvombo zvine simba, zvichibvumira T-masero kuti aone uye arwise masero ekenza zvakanyanya.
Iwe ungafara kuziva kuti vangangoita 70% yevarwere vegomarara vanopindura zvakanaka kune iyo CAR T cell therapy kurapwa muIndia zvakanaka.
Tarisa Izvi: Basa reImmunotherapy Mukurapa Lymphoma - CancerFax
Kurapa Kwegomarara Kutsva Uku Kunokwanisika Here?
Nhau dzakanaka kune vese varwere vegomarara kunze uko! The Mumbai-based Immunoact itsva kenza kurapwa, NexCAR19, yakagamuchira mvumo.
Ndezve leukemia uye varwere ve lymphoma vasina kupindura kune mamwe marapirwo. The mutengo weCAR T cell kurapwa muIndia inenge USD 57,000, iyo yakachipa kupfuura mune dzimwe nzvimbo dzakawanda.
Izvi zvinoreva India inogona kuve imwe yedzakanakisa uye inokwanisika nzvimbo dzekurapwa kwegomarara, ichipa tariro kune avo vanoida.
Mhando dzeCancer Yakarapwa neCAR T Cell Process
Kurapa kwegomarara uku kunonyanya kushanda kune varwere vegomarara vasina kupindura chemotherapy uye mamwe marapirwo egomarara. Kurapa uku kwakaratidza mimwe mibairo inovimbisa mukurapa marudzi akasiyana-siyana e gomarara reropa. Heino rondedzero yeakajairika mota t cell therapy application:
Multiel Myeloma
Multiple myeloma imhando yegomarara rinonyanya kunanga masero eplasma, ayo ari zvikamu zvakakosha zve immune system inokonzeresa kugadzirwa kweantibody.
Mumamiriro ezvinhu aya, masero eplasma asina kujairika anowanda zvisingadzoreki, achivhara kunze masero akajairika mumwongo wepfupa. Immunotherapy uye stem cell transplantation ndiyo inonyanya kushanda akawanda myeloma kurapwa muIndia.
B-cell Acute Lymphoblastic Leukemia
B-cell acute lymphoblastic leukemia (B-ALL) imhando yegomarara inokanganisa immature B lymphocytes, boka chairo remasero machena eropa, panguva yekukura kwavo mumwongo.
Panzvimbo pokukura kuva masero machena eropa ane utano, aya masero asati akura anova asina kujairika uye anokurumidza kuwanda, achivharidzira kunze anowanzogara. Kurapa chirwere ichi, vanachiremba vanowanzoshandisa musanganiswa wekemotherapy uye mapfupa emapfupa.
B-cell Non-Hodgkin Lymphoma
Kune akati wandei masubtypes eB-cell isiri-Hodgkin lymphoma (B-NHL), kusanganisira diffuse hombe B-cell lymphoma (DLBCL), follicular lymphoma ine DLBCL, uye yepamusoro-giredhi B-cell lymphoma.
Aya magomarara anobva kuB lymphocytes, rudzi rwesero jena reropa, uye anoiswa mumapoka zvichienderana nehunhu hwawo hwakasiyana. Mutariri wako wehutano anogona kugadzirisa chirwere ichi nechemotherapy, stem cell transplants, uye monoclonal antibodies.
Mantle Cell Lymphoma
Mantle cell lymphoma is a subtype ye-non-Hodgkin lymphoma inotangira muB lymphocytes. Iyi chaiyo fomu ye lymphoma inoratidzirwa nekukura nokukurumidza kwemasero ane kenza, anowanzopinda mumhando dzakasiyana-siyana dze lymphoid. Mantle cell lymphoma inowanzobatwa nemusanganiswa wechemotherapy uye stem cell transplantation.
Nhanho-Ne-Nhanho Maitiro ECAR T Cell Therapy
1. Pakutanga, mutarisiri wako wehutano anoisa chubhu diki (catheter) mutsinga yemutsipa wako kana pasi pecollarbone yako.
2. Vanobatanidza catheter kumuchina wechirongwa chinonzi leukapheresis. Muchina uyu unobata ropa rako, uchiburitsa masero machena eropa uye uchidzosera masero matsvuku eropa uye plasma kudzokera mumuviri wako.
3. Pashure pacho, utachiona husina kushanda hunounzwa kuti hupe mirayiridzo mitsva yemajini kumaT-cell ako.
4. T-masero ako anotanga kugadzira chimeric antigen receptors (CAR) uye mamorekuru akashongedzerwa nemirairo mitsva yemajini.
5. MaCAR receptors anoguma ari pamusoro peT-cells ako, nepo mamorekuru anoramba ari mukati, achipa masaini ekuchengetedza maT-cell ako achishanda.
6. Batch duku reCAR T-cells rinokurudzirwa kuti riwande uye rikure kusvika rave rakakwana kunanga masero egomarara zvakanaka. Masero aya anoomeswa nechando uye anochengetwa mufiriji kusvika ave kudiwa.
7. Usati wagamuchira masero matsva, uchaitwa chemotherapy kudzivirira immune system yako kubva pakuaramba.
8. Kutevera chemotherapy, uchagamuchira masero matsva kuburikidza nekupinza, mungave muchipatara kwemazuva akawanda kana, mune mamwe mamiriro ezvinhu, pasina kugara muchipatara, pasi pekutariswa kweboka rako rehutano.
9. Kana yangopinda muropa rako, CAR T-cell receptors inoziva uye inosunga kune maantigen (mapuroteni) pamasero ekenza.
10. Masero ako eCAR T anobva awanda otanga kuuraya cancer maseru nemazvo. Yako CAR T-masero anoramba achikura uye achitsvaga masero matsva ane chinangwa cheantigen kuti ave nechokwadi chekudzivirira kwenguva refu kurwisa cancer.
CAR T Cell Therapy Side Migumisiro Yaunofanirwa Kuziva
Cytokine Release Syndrome
Izvi zvinowanzoitika apo iyo yakaisirwa CAR T-masero inokonzeresa kuburitswa kwemacytokines, zvichitungamira kune zviratidzo zvakaita sefivha, kuderera kweropa, uye kunetseka kufema.
Neurological Toxicity
Vamwe vanhu vanogona kusangana nekuvhiringika, kubatwa, kana zvimwe zvinhu zvetsinga nekuda kwekukanganisa kweCAR T-cell therapy pane yepakati tsinga system.
Kudzvinyirirwa kweBone Marrow
CAR T-cell therapy inogona kudzikamisa kwechinguva kugadzirwa kwemasero eropa mumwongo, zvichikonzera kuderera kwemasero matsvuku eropa, masero machena eropa, uye maplatelet.
zvirwere
Varwere vane simba rekudzivirira zvirwere, kunyanya panguva yekutanga mushure mekurapa, vanonyanya kutarisana nehutachiona.
Final Thoughts
Apo tirikupeta ongororo yedu yeCAR T Cell Process, ngatitakurei ruzivo rwekuti sainzi iri kuvhura nzira itsva mukurwisa gomarara.
Iyo CAR T cell maitiro inopfuura kungoita kurapwa; umboo hwezvinoshamisa kufambira mberi kuri kuitwa mukurapwa kwegomarara.
Saka, kune vese avo vakashinga vakatarisana nedambudziko iri, zivai kuti nyika yemishonga iri kusimukira, uye nhanho imwe neimwe yekuenda mberi inhanho yekuenda kune ramangwana rakajeka, rine hutano. Tinokushuvira iwe kupora nekukurumidza uye neramangwana rine hutano!
